A COVID-19 and clinical study update propelled a Canadian biopharma stock Thursday. Here’s some small stocks making big moves on Thursday, July 2, 2020 (as of 4 pm EST):
Liminal BioSciences Inc. (TSX:LMNL), a Canadian biopharma stock, surged 62% to $23 on Thursday after announcing that its multiple ascending dose Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020. The Company also reported that its Prometic Plasma Resources subsidiary has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
As well, shares of Prime Mining Corp. (TSXV:PRYM) gained 9% to $1.42 as the junior explorer revealed sample results from the Company’s ongoing surface exploration program on the Los Reyes project in Mexico, which included 63.0 metres of 1.78 grams per tonne (g/t) gold and 71.0 g/t silver.
Meanwhile, Global Crossing Airlines Inc. (TSXV:JET), formerly Canada Jetlines, reported that it and Breeze Airways have reached an amicable agreement to settle a lawsuit brought by Canada Jetlines in November 2019. Global Crossing Airlines stock flew 39% to $2.55 following the announcement.
Finally, Datametrex AI Limited (TSXV:DM) shares rose 18% to $0.10 after the Artificial Intelligence and Machine Learning focused technology company announced a $2.6 million per annum sales agreement with SeeS Solutions Inc.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Liminal BioSciences Inc. (TSX:LMNL), a Canadian biopharma stock, surged 62% to $23 on Thursday after announcing that its multiple ascending dose Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020. The Company also reported that its Prometic Plasma Resources subsidiary has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
, on Thursday.){kind=link}